Literature DB >> 2410271

Insulin receptors and bioresponses in a human liver cell line (Hep G-2).

J M Podskalny, S Takeda, R E Silverman, D Tran, J L Carpentier, L Orci, P Gorden.   

Abstract

A newly developed human hepatoma cell line, designated Hep G-2, expresses high-affinity insulin receptors meeting all the expected criteria for classic insulin receptors. 125I-insulin binding is time-dependent and temperature-dependent and unlabeled insulin competes for the labeled hormone with a half-maximal displacement of 1-3 ng/ml. This indicates a Kd of about 10(-10) M. Since Scatchard analysis of the binding data results in a curvilinear plot and unlabeled insulin accelerates the dissociation of bound hormone, these receptors exhibit the negative cooperative interactions characteristic of insulin receptors in many other cell and tissue types. Proinsulin and des(Ala, Asp)-insulin compete for 125I-insulin binding with 4% and 2%, respectively, of the potency of insulin. Anti-(insulin receptor) antibody competes fully for insulin binding. The two insulin-like growth factors, multiplication-stimulating activity and IGF-I are 2% as potent as insulin against the Hep G-2 insulin receptor. Furthermore, Hep G-2 cells respond to insulin in several bioassays. Glucose uptake, glycogen synthase, uridine incorporation into RNA and acetate incorporation into lipid are all stimulated to varying degrees by physiological concentrations of insulin. In addition, these cells 'down-regulate' their insulin receptor, internalize 125I-insulin and degrade insulin in a manner similar to freshly isolated rodent hepatocytes. This is the first available human liver cell line in permanent culture in which both insulin receptors and biological responses have been carefully examined.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2410271     DOI: 10.1111/j.1432-1033.1985.tb09034.x

Source DB:  PubMed          Journal:  Eur J Biochem        ISSN: 0014-2956


  9 in total

1.  Interaction of non-esterified fatty acid and insulin in control of triacylglycerol secretion by Hep G2 cells.

Authors:  C D Byrne; N P Brindle; T W Wang; C N Hales
Journal:  Biochem J       Date:  1991-11-15       Impact factor: 3.857

2.  Complementation of a methotrexate uptake defect in Chinese hamster ovary cells by DNA-mediated gene transfer.

Authors:  T M Underhill; W F Flintoff
Journal:  Mol Cell Biol       Date:  1989-04       Impact factor: 4.272

3.  Lack of a lipoprotein-induced insulin resistance in hepatoma cells in culture.

Authors:  F Rinninger; B Wolf; H U Haering; W Bachmann
Journal:  Diabetologia       Date:  1986-07       Impact factor: 10.122

4.  Identification of unique nuclear regulatory proteins for the insulin receptor gene, which appear during myocyte and adipocyte differentiation.

Authors:  A Brunetti; D Foti; I D Goldfine
Journal:  J Clin Invest       Date:  1993-09       Impact factor: 14.808

5.  Reciprocal regulation of glycogen phosphorylase and glycogen synthase by insulin involving phosphatidylinositol-3 kinase and protein phosphatase-1 in HepG2 cells.

Authors:  N A Syed; R L Khandelwal
Journal:  Mol Cell Biochem       Date:  2000-08       Impact factor: 3.396

6.  Insulin receptor desensitization correlates with attenuation of tyrosine kinase activity, but not of receptor endocytosis.

Authors:  A D Blake; N S Hayes; E E Slater; C D Strader
Journal:  Biochem J       Date:  1987-07-15       Impact factor: 3.857

7.  Acute insulin action requires insulin receptor kinase activity: introduction of an inhibitory monoclonal antibody into mammalian cells blocks the rapid effects of insulin.

Authors:  D O Morgan; R A Roth
Journal:  Proc Natl Acad Sci U S A       Date:  1987-01       Impact factor: 11.205

8.  alpha-Fucose-mediated binding and degradation of tissue-type plasminogen activator by HepG2 cells.

Authors:  K A Hajjar; C M Reynolds
Journal:  J Clin Invest       Date:  1994-02       Impact factor: 14.808

9.  Expression of apolipoprotein M and its association with adiponectin in an obese mouse model.

Authors:  Liu Yang; Tie Li; Shuiping Zhao; Saidan Zhang
Journal:  Exp Ther Med       Date:  2019-07-09       Impact factor: 2.447

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.